Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

Journal of Hepatology

Volumn 68, Issue 6, 2018, Pages 1181-1190

  De Martin, Eleonora ^a   Michot, Jean Marie ^b   Papouin, Barbara ^c   Champiat, Stéphane ^b   Mateus, Christine ^b   Lambotte, Olivier ^d   Roche, Bruno ^a   Antonini, Teresa Maria ^a   Coilly, Audrey ^a   Laghouati, Salim ^b   Robert, Caroline ^b   Marabelle, Aurélien ^b   Guettier, Catherine ^c   Samuel, Didier ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c BICÊTRE HOSPITAL   (France)

^d INSERM   (France)

Author keywords

Immune checkpoints inhibitors; Immune related adverse events; Immunotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; DURVALUMAB; GAMMA GLUTAMYLTRANSFERASE; IPILIMUMAB; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR FOXP3; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE HEPATITIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; BLADDER CARCINOMA; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CUTANEOUS MELANOMA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRANULOMA ANNULARE; GRANULOMATOUS HEPATITIS; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOPHYSITIS; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER HISTOLOGY; LUNG CARCINOMA; MACULOPAPULAR RASH; MAINTENANCE DRUG DOSE; MALE; MELANOMA; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; RENAL CELL CARCINOMA; SIDE EFFECT; THYROIDITIS; TOXIC HEPATITIS; VERY ELDERLY; ADVERSE EVENT; HEPATITIS; IMMUNOLOGY; IMMUNOTHERAPY; INJURY; LIVER; NEOPLASM; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CTLA-4 ANTIGEN; FEMALE; HEPATITIS; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; LIVER; MALE; MIDDLE AGED; NEOPLASMS; NIVOLUMAB;

EID: 85044253460     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.01.033     Document Type: Article

References (37)

1. Hodi, F.S., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K.F., McDermott, D.F., et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17 (2016), 1558–1568.
2. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
3. Pardoll, D., Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol 42 (2015), 523–538.
4. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
5. Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16 (2016), 275–287.
6. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
7. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
8. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
9. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.-J., Topalian, S.L., Hwu, P., et al. Safety and activity of Anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
10. Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148.
11. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
12. O'Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol: Official J Eur Soc Med Oncol 21 (2010), 1712–1717.
13. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
14. Johncilla, M., Misdraji, J., Pratt, D.S., Agoston, A.T., Lauwers, G.Y., Srivastava, A., et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39 (2015), 1075–1084.
15. Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44 (2016), 51–60.
16. Hofmann, L., Forschner, A., Loquai, C., Goldinger, S.M., Zimmer, L., Ugurel, S., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 190–209.
17. Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol: Official J Eur Soc Med Oncol 27 (2016), 559–574.
18. Fontana, R.J., Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 146 (2014), 914–928.
19. Fontana, R.J., Engle, R.E., Scaglione, S., Araya, V., Shaikh, O., Tillman, H., et al. The role of hepatitis E virus infection in adult Americans with acute liver failure. Hepatology 64 (2016), 1870–1880.
20. Del Castillo, M., Romero, F.A., Arguello, E., Kyi, C., Postow, M.A., Redelman-Sidi, G., The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis: An official publication of the Infect Dis Soc Am 63 (2016), 1490–1493.
21. Weber, J.S., Gibney, G., Sullivan, R.J., Sosman, J.A., Slingluff, C.L. Jr., Lawrence, D.P., et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 17 (2016), 943–955.
22. Zhang, X., Ran, Y., Wang, K., Zhu, Y., Li, J., Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Devel Ther 10 (2016), 3153–3161.
23. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
24. Ribas, A., Hodi, F.S., Callahan, M., Konto, C., Wolchok, J., Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368 (2013), 1365–1366.
25. Spengler, E.K., Kleiner, D.E., Fontana, R.J., Vemurafenib-induced granulomatous hepatitis. Hepatology 65 (2017), 745–748.
26. Murphy, K.P., Kennedy, M.P., Barry, J.E., O'Regan, K.N., Power, D.G., New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 37 (2014), 351–353.
27. Andersen, R., Norgaard, P., Al-Jailawi, M.K., Svane, I.M., Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology, 3, 2014, e954506.
28. Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza Stalder, J., et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol: Official J Am Soc Clin Oncol 30 (2012), e156–e159.
29. Everett, J., Srivastava, A., Misdraji, J., Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol 41 (2017), 134–137.
30. Simonelli, M., Di Tommaso, L., Baretti, M., Santoro, A., Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy 8 (2016), 1363–1369.
31. Ziemer, M., Koukoulioti, E., Beyer, S., Simon, J.C., Berg, T., Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 66 (2017), 657–659.
32. Naidoo, J., Page, D.B., Li, B.T., Connell, L.C., Schindler, K., Lacouture, M.E., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26 (2015), 2375–2391.
33. Chmiel, K.D., Suan, D., Liddle, C., Nankivell, B., Ibrahim, R., Bautista, C., et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol: Official J Am Soc Clin Oncol 29 (2011), e237–e240.
34. Indini, A., Di Nicola, M., Del Vecchio, M., De Braud, F., Immune suppression and response to ipilimumab: assessing risk-to-benefit ratio. J Clin Oncol: Official J Am Soc Clin Oncol 34 (2016), 1017–1018.
35. Downey, S.G., Klapper, J.A., Smith, F.O., Yang, J.C., Sherry, R.M., Royal, R.E., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res: An official J Am Assoc Cancer Res 13 (2007), 6681–6688.
36. Horvat, T.Z., Adel, N.G., Dang, T.O., Momtaz, P., Postow, M.A., Callahan, M.K., et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan kettering cancer center. J Clin Oncol: Official J Am Soc Clin Oncol 33 (2015), 3193–3198.
37. Weber, J.S., Antonia, S.J., Topalian, S.L., Schadendorf, D., Larkin, J.M.G., Sznol, M., et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol, 33, 2015 9018–9018.